{"prompt": "['Novartis', 'Confidential', 'Page 49', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'Daytime symptom diary scale questions', 'How often did you experience asthma symptoms today?', '0', '1', '2', '3', '4', '5', '6', 'None of', 'All of', 'the time', 'the time', 'How much did your asthma symptoms bother you today?', '0', '1', '2', '3', '4', '5', '6', 'Not at all', 'Severely', 'bothered', 'bothered', 'How much activity could you do today?', '0', '1', '2', '3', '4', '5', '6', 'More than', 'Less than', 'usual activity', 'usual activity', 'How often did your asthma affect your activities today?', '0', '1', '2', '3', '4', '5', '6', 'None of', 'All of', 'the time', 'the time', '6.4.2.2 Number of inhalations of rescue medication', 'The total number of inhalations used of SABA (number of puffs taken in the previous 12', 'hours) will be recorded morning and evening by the patient, in the eDiary/ePEF.']['Novartis', 'Confidential', 'Page 50', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', '6.4.2.4 Worsening of asthma (and related eDiary alerts)', 'Asthma worsening criteria will be programmed into the eDiary/ePEF.', 'The data captured in the eDiary/ePEF will be used to alert the patient and/or investigator to', 'possible signs of worsening asthma. These alerts include:', 'An increase in SABA use on at least 2 of any 3 consecutive days exceeding the equivalent', 'of 8 puffs/day (diary alert).', 'Night time awakenings requiring SABA use on at least 2 out of any 3 consecutive nights', '(diary alert).', '<60% of PEF compared to baseline (diary alert).', \"The patient's personal best PEF in the clinic at Visit 101 will be set as the patient's baseline\", 'for the placebo run-in period, and the personal best PEF in the clinic at Visit 199 before', \"dosing will be set as the patient's baseline for the treatment period.\", 'If patients develop any of the above criteria, the patient should notify the investigator and be', 'evaluated by the investigator and treated as clinically appropriate.', 'If any of these criteria are met while a patient is in the screening, placebo run-in, or treatment', 'periods of the study, they may be withdrawn if, in the opinion of the investigator, it is', 'appropriate to do so.', 'Worsening of asthma symptoms may require unscheduled evaluation between visits. Study', \"site personnel must be available to monitor and document the patient's progress until the\", 'asthma worsening has resolved.', '6.4.3', 'Asthma exacerbations', 'The following definitions of exacerbations are used in this study:', 'A severe asthma exacerbation is defined as', 'treatment with \"rescue\\' systemic corticosteroids for greater than or equal to 3 days and', 'hospitalization; or', 'treatment with \"rescue\\' systemic corticosteroids for greater than or equal to 3 days and', 'emergency department visit (greater than 24 hours*); or', 'death due to asthma.', 'A moderate asthma exacerbation is defined as', 'treatment with \"rescue\\' systemic corticosteroids for greater than or equal to 3 days either', 'as an outpatient or in emergency department visits (Emergency department visit less than', 'or equal to 24 hours).', '*An emergency room visit greater than 24 hours is considered to be a hospitalization', '\"Rescue\\' systemic corticosteroids are tablets, suspension, or injection, or an increase of a', \"patient's maintenance systemic corticosteroids of greater than 2 fold (i.e., greater than\", 'doubling the maintenance dose of systemic corticosteroids). A single depo-injectable dose of', 'corticosteroid will be considered the equivalent to a 3-day course of systemic steroids (Reddel', 'et al 2009). Endotracheal intubations will be captured on the CRF.']['Novartis', 'Confidential', 'Page 51', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'Scheduled spirometry must not be performed during an exacerbation until it has completely', 'resolved.', 'Patients experiencing an asthma exacerbation during the screening or placebo run-in periods', 'must be designated as screening or run-in failures. Patients who experience an asthma', 'exacerbation during screening may be re-screened 4 weeks after complete recovery from the', 'exacerbation.', '6.4.4', 'Appropriateness of efficacy assessments', 'The measurements described above are standard outcome measures in asthma trials.', '6.5', 'Safety', 'The following safety assessments as delineated in Table 6-1 will be performed:', 'History and physical examination', 'Vital signs', 'Hematology', 'Blood chemistry including but not limited to', 'Liver function tests: ALT, AST, total bilirubin', 'Metabolic panel: sodium, potassium, chloride, bicarbonate, blood urea nitrogen', '(BUN)/urea, creatinine, glucose, calcium, phosphorus, magnesium, total protein,', 'albumin (Alb), gamma-glucoronyl transferase (y-GT), alkaline phosphatase (ALP),', 'lactate dehydrogenase (LDH), creatine kinase (CK), iron, uric acid, cholesterol,', 'triglycerides', 'amylase, lipase', 'High sensitivity C-reactive protein (hsCRP)', 'Creatine kinase isoenzyme-MB (CK-MB) and Troponin-I (in response to CK results', 'outside of the normal range)', 'Glycosylated hemoglobin (HbA1c) (collected at Visit 1 only)', 'Urinalysis and urine chemistry', 'Pregnancy test (Pregnancy testing will begin at the visit when a patient is first identified', 'as being of child bearing potential)', 'ECG', 'Adverse events including serious adverse events', 'Spirometry will also be used to monitor the safety of patients during the study. Patients will', 'be provided with an eDiary/ePEF. The data captured in the eDiary/ePEF will be used to alert', 'the patient and/or investigator to possible signs of worsening asthma.', 'A central laboratory will be used to analyze and report blood chemistry/hematology and', 'urinalysis/ urine chemistry. A central ECG vendor will be used to collect, assess and report', 'ECGs.', 'A Data Monitoring Committee will be set up to overview safety. See Section 8.4 for details.']\n\n###\n\n", "completion": "END"}